| Ticker Details |
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.
|
| IPO Date: |
September 1, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.96B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.23 | 2.67%
|
| Avg Daily Range (30 D): |
$0.27 | 1.70%
|
| Avg Daily Range (90 D): |
$0.24 | 1.61%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.71M |
| Avg Daily Volume (30 D): |
.99M |
| Avg Daily Volume (90 D): |
.9M |
| Trade Size |
| Avg Trade Size (Sh.): |
164 |
| Avg Trade Size (Sh.) (30 D): |
73 |
| Avg Trade Size (Sh.) (90 D): |
67 |
| Institutional Trades |
| Total Institutional Trades: |
2,683 |
| Avg Institutional Trade: |
$1.31M |
| Avg Institutional Trade (30 D): |
$1.73M |
| Avg Institutional Trade (90 D): |
$1.71M |
| Avg Institutional Trade Volume: |
.11M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.38M |
| Avg Closing Trade (30 D): |
$1.83M |
| Avg Closing Trade (90 D): |
$1.87M |
| Avg Closing Volume: |
129.22K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$2.26
|
$.26
|
$1.6
|
|
Diluted EPS
|
$2.17
|
$.25
|
$1.53
|
|
Revenue
|
$298.3M
|
$77.71M
|
$77.11M
|
|
Gross Profit
|
$267.7M
|
$71.2M
|
$68.32M
|
|
Net Income / Loss
|
$298.21M
|
$34.36M
|
$210.79M
|
|
Operating Income / Loss
|
$124.49M
|
$41.42M
|
$33.24M
|
|
Cost of Revenue
|
$30.6M
|
$6.51M
|
$8.8M
|
|
Net Cash Flow
|
$-25.42M
|
$-39.21M
|
$7.02M
|
|
PE Ratio
|
|
|
|
|
|
|
